Tela Bio Inc Cash Flow Conversion Efficiency
Tela Bio Inc cash flow conversion efficiency. Based on the latest financial reports, Tela Bio Inc (TELA) has a cash flow conversion efficiency ratio of 0.591x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.38 Million) by net assets ($-15.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tela Bio Inc (2017–2025)
Cash flow conversion efficiency of Tela Bio Inc from 2017 to 2025. This chart illustrates how Tela Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Tela Bio Inc stock price for real-time trading data and today's change.
Tela Bio Inc Cash Flow Conversion Ratio Explained
Tela Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tela Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tela Bio Inc ranked by their cash flow conversion efficiency. Also see how much is Tela Bio Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hammer Metals Ltd
AU:HMX
|
-0.028x |
|
INFOMARK Co. Ltd
KQ:175140
|
0.056x |
|
NBI Bearings Europe S.A.
MC:NBI
|
0.043x |
|
Woory Industrial Co. Ltd
KQ:215360
|
0.034x |
|
S&S Power Switchgears Limited
NSE:S&SPOWER
|
-0.163x |
|
IBKS No2 SPAC
KQ:204840
|
0.053x |
|
Beaconsmind AG
PA:MLBMD
|
-1.608x |
|
TAEYANG Corporation
KQ:053620
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Tela Bio Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Tela Bio Inc from 2017 to 2025. Review financial agility of Tela Bio Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.31 Million | $-28.22 Million | -4.470x | -205.82% |
| 2024-12-31 | $28.46 Million | $-41.59 Million | -1.462x | +32.45% |
| 2023-12-31 | $18.88 Million | $-40.86 Million | -2.164x | +24.03% |
| 2022-12-31 | $14.30 Million | $-40.75 Million | -2.849x | -88.12% |
| 2021-12-31 | $20.10 Million | $-30.43 Million | -1.514x | -203.54% |
| 2020-12-31 | $49.03 Million | $-24.46 Million | -0.499x | +39.49% |
| 2019-12-31 | $30.96 Million | $-25.52 Million | -0.824x | -670.38% |
| 2018-12-31 | $-137.86 Million | $-19.92 Million | 0.145x | -4.49% |
| 2017-12-31 | $-108.17 Million | $-16.37 Million | 0.151x | -- |
About Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue… Read more